Coya Therapeutics reported revenue of $0.24M and net income of -$6.64M for the quarter ended Jun 2026, up 49.0% year over year. This income statement covers 19 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||
| Revenue | 6.00M | 0.13M | 3.43M | 0.00M | 0.26M | 0.16M | 3.56M | 3.96M | 0.25M | 0.24M | |||||||||
| Operating items | |||||||||||||||||||
| Depreciation & Amortization - TotalDep. & Amort. (Tot) | 0.00M | 0.00M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M | |
| Research & DevelopmentR&D | 0.98M | 1.45M | 1.28M | 0.71M | 1.23M | 1.07M | 1.59M | 1.61M | 3.14M | 4.57M | 2.22M | 1.94M | 5.21M | 3.66M | 2.92M | 4.94M | 4.10M | 5.03M | |
| Selling, General & AdministrativeSG&A | 0.72M | 1.99M | 1.24M | 0.90M | 1.66M | 1.83M | 1.96M | 2.38M | 2.44M | 2.09M | 2.22M | 2.14M | 2.71M | 2.91M | 2.56M | 3.27M | 3.78M | 2.26M | |
| Restructuring CostsRestructuring | 1.50M | 1.05M | 1.08M | 0.99M | 1.33M | 1.55M | 1.18M | 1.48M | 1.29M | 1.18M | |||||||||
| Other Operating ExpensesOther Opex | 0.14M | 0.39M | 0.35M | 0.19M | -1.47M | -1.05M | -1.08M | -0.99M | -1.33M | -1.55M | -0.67M | 0.29M | -1.28M | -1.18M | |||||
| Operating ExpensesOpex | 1.70M | 3.45M | 2.66M | 2.00M | 2.90M | 3.25M | 3.56M | 4.19M | 5.61M | 6.66M | 4.45M | 4.08M | 7.93M | 6.58M | 6.00M | 9.99M | 7.89M | 7.29M | |
| Operating IncomeOp. Inc | -1.70M | -3.45M | -2.66M | -2.00M | -2.90M | -3.25M | -3.56M | 1.82M | -5.48M | -3.24M | -4.45M | -4.08M | -7.68M | -6.41M | -2.43M | -6.03M | -7.64M | -7.05M | |
| EBIT | -1.70M | -3.45M | -2.66M | -2.00M | -2.90M | -3.25M | -3.56M | 1.82M | -5.48M | -3.24M | -4.45M | -4.08M | -7.68M | -6.41M | -2.43M | -6.03M | -7.64M | -7.05M | |
| Non-operating items | |||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | 0.01M | 0.04M | 0.02M | 0.16M | 0.16M | 0.14M | 0.17M | 0.43M | 0.34M | 0.43M | 0.44M | 0.37M | 0.32M | 0.32M | 0.41M | 0.43M | 0.41M | |
| Net income details | |||||||||||||||||||
| EBT | -1.70M | -3.45M | -2.66M | -2.00M | -2.90M | -3.25M | -3.56M | 1.82M | -5.05M | -2.89M | -4.45M | -4.08M | -7.31M | -6.09M | -2.43M | -6.03M | -7.21M | -6.64M | |
| Profit After TaxPAT | -1.70M | -3.41M | -4.02M | -3.11M | -2.74M | -3.10M | -3.42M | 1.27M | -5.05M | -2.89M | -4.02M | -2.92M | -7.31M | -6.09M | -2.12M | -5.71M | -7.21M | -6.64M | |
| Income from Continuing OperationsIncome (Continuing) | -1.70M | -3.45M | -2.66M | -2.00M | -2.90M | -3.25M | -3.56M | 1.82M | -5.05M | -2.89M | -4.45M | -4.08M | -7.31M | -6.09M | -2.43M | -6.03M | -7.21M | -6.64M | |
| Consolidated Net IncomeConsol Net Inc. | -1.70M | -3.45M | -2.66M | -2.00M | -2.90M | -3.25M | -3.56M | 1.82M | -5.05M | -2.89M | -4.45M | -4.08M | -7.31M | -6.09M | -2.43M | -6.03M | -7.21M | -6.64M | |
| Income towards Parent CompanyParent Net Inc | -1.70M | -3.45M | -2.66M | -2.00M | -2.90M | -3.25M | -3.56M | 1.82M | -5.05M | -2.89M | -4.45M | -4.08M | -7.31M | -6.09M | -2.43M | -6.03M | -7.21M | -6.64M | |
| Net Income towards Common StockholdersNet Income | -1.70M | -3.45M | -2.66M | -2.00M | -2.90M | -3.25M | -3.56M | 1.82M | -5.05M | -2.89M | -4.45M | -4.08M | -7.31M | -6.09M | -2.43M | -6.03M | -7.21M | -6.64M | |
| Additional items | |||||||||||||||||||
| EPS (Basic) | -0.66 | -1.33 | -1.03 | -0.77 | -0.30 | -0.33 | -0.36 | 0.18 | -0.35 | -0.19 | -0.29 | -0.27 | -0.44 | -0.36 | -0.15 | -0.36 | -0.32 | -0.28 | |
| EPS (Diluted) | -0.66 | -1.33 | -1.03 | -0.77 | -0.30 | -0.33 | -0.36 | 0.18 | -0.35 | -0.19 | -0.29 | -0.27 | -0.44 | -0.36 | -0.15 | -0.36 | -0.32 | -0.28 | |
| Shares Outstanding | 2.59M | 2.59M | 2.59M | 2.59M | 2.59M | 9.72M | 9.95M | 9.95M | 10.16M | 14.46M | 14.92M | 15.22M | 15.24M | 16.72M | 16.72M | 16.73M | 16.73M | 22.64M | 23.46M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 2.59M | 2.59M | 2.59M | 2.59M | 2.59M | 9.72M | 9.95M | 9.95M | 10.16M | 14.46M | 14.92M | 15.22M | 15.24M | 16.72M | 16.72M | 16.73M | 16.73M | 22.64M | 23.46M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.59M | 2.59M | 2.59M | 2.59M | 2.59M | 9.95M | 9.95M | 9.95M | 10.16M | 14.61M | 15.22M | 15.22M | 16.71M | 16.72M | 16.72M | 16.74M | 16.73M | 23.46M | 23.46M |
| EBITDA | -1.70M | -3.44M | -2.65M | -2.00M | -2.89M | -3.25M | -3.56M | 1.82M | -5.48M | -3.23M | -4.44M | -4.07M | -7.67M | -6.41M | -2.43M | -6.02M | -7.64M | -7.04M |